Neuromeka CEO Jonghoon Park Plans OTC Sale of Shares and Warrants to Fund Rights Offering Subscription
Neuromeka CEO and major shareholder Jonghoon Park plans to sell 70,000 common shares and 483,612 warrants over-the-counter from July 6 to July 20, 2026.
The purpose is to raise funds for subscribing to the rights offering of unsubscribed shares after shareholder allocation, with an estimated transaction value of approximately 22.5 billion KRW.
After the sale, Park's ownership will decrease from 21.40% to 17.80%, reflecting a temporary stake reduction for funding purposes.
This transaction does not involve any change in the company's capital structure and has no direct dilution effect on shareholder value.
[AI Summary]The CEO's partial stake sale to fund rights offering participation does not alter the company's capital structure, but the reduction in insider ownership and large sell order may exert short-term pressure on the stock price.
KOSDAQ Filing Information
Report On Transaction Plan Of Specific Securities By Executives And Major Shareholders